Literature DB >> 25940570

CT Signs Can Predict Treatment Response and Long-Term Survival: A Study in Locally Advanced Esophageal Cancer with Preoperative Chemotherapy.

Xiao-Yan Zhang1, Wan-Pu Yan2, Yu Sun3, Xiao-Ting Li1, Ying Chen1, Meng-Ying Fan2, Ying Wu3, Zhen Liang2, Hong-Chao Xiong2, Zhi-Long Wang1, Ying-Shi Sun4, Ke-Neng Chen5.   

Abstract

BACKGROUND: Accurate prediction of treatment response and prognosis before surgery allows prompt therapy adjustment. This study aimed to evaluate the efficacy of computed tomography (CT) signs in predicting treatment response and survival for advanced esophageal squamous cell carcinoma patients who received preoperative chemotherapy.
METHODS: This study retrospectively enrolled 135 consecutive patients with preoperative chemotherapy from September 2005 to December 2011. A logistic regression model was used to evaluate the association between pathologic response and CT signs. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and a Cox proportional hazards model was constructed to determine associations between CT signs after neoadjuvant chemotherapy and survival outcomes.
RESULTS: Logistic regression showed that the significant predictors of a poor response were the total number of lymph nodes (LNs) (>6) at baseline [odds ratio (OR) 5.07; 95 % confidence interval (CI) 1.86-13.81; P = 0.002] and the CT value change rate (≤17 %) (OR 2.35; 95 % CI 1.05-5.23; P = 0.037). In the Cox analyses, the significant predictors of OS were preoperative tumor thickness (>10 mm) [hazard ratio (HR) 2.33; 95 % CI 1.36-4; P = 0.002), total number of LNs (>6) (HR 1.88; 95 % CI 1.12-3.17; P = 0.017), and short diameter of the largest LN (>10 mm) (HR 1.87; 95 % CI 1.07-3.28; P = 0.028), whereas only the short diameter of the largest LN was a significant predictor of DFS (HR 2.36; 95 % CI 1.23-4.54; P = 0.01).
CONCLUSIONS: CT signs can predict therapeutic efficacy and survival outcomes and provide an opportunity to offer additional treatment options before surgery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25940570     DOI: 10.1245/s10434-015-4531-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.

Authors:  Sohei Matsumoto; Kohei Wakatsuki; Hiroshi Nakade; Tomohiro Kunishige; Shintaro Miyao; Akinori Tsujimoto; Takanari Tatsumi; Masayuki Sho
Journal:  Langenbecks Arch Surg       Date:  2022-01-06       Impact factor: 3.445

2.  Prognostic value of computed tomography characteristics for overall survival in patients with maxillary cancer.

Authors:  Ying Yuan; Jingbo Wang; Yingwei Wu; Guojun Li; Xiaofeng Tao
Journal:  BMC Cancer       Date:  2016-10-10       Impact factor: 4.430

3.  Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.

Authors:  Yue Li; Jun Liu; Hong-Xuan Li; Xu-Wei Cai; Zhi-Gang Li; Xiao-Dan Ye; Hao-Hua Teng; Xiao-Long Fu; Wen Yu
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

4.  DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer.

Authors:  Jinrong Qu; Ling Ma; Yanan Lu; Zhaoqi Wang; Jia Guo; Hongkai Zhang; Xu Yan; Hui Liu; Ihab R Kamel; Jianjun Qin; Hailiang Li
Journal:  Discov Oncol       Date:  2022-01-08

5.  A Pilot Study of Prognostic Value of Metastatic Lymph Node Count and Size in Patients with Different Stages of Gastric Carcinoma.

Authors:  Yong Gao; Kun Wang; Xiao-Xian Tang; Jin-Liang Niu; Jun Wang
Journal:  Cancer Manag Res       Date:  2022-06-21       Impact factor: 3.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.